Type 2 diabetes is relatively widespread in Japan, and that nation’s Ministry of Health, Labour and Welfare estimates that nearly one-third of all individuals over the age of 40 are either diabetic or pre-diabetic.
Intriguingly, Japanese patients as a whole are less prone to obesity, a condition commonly associated with onset of type 2 diabetes in the Western world, indicating that there may be some significant differences in disease pathology between these two groups.
Two primary mechanisms contribute to the onset of type 2 diabetes. Fat, muscle and liver cells lose the ability to respond to the hormone insulin, a state known as ‘insulin resistance’ that greatly reduces the efficiency with which excess glucose is taken up from the bloodstream; in parallel, the capacity of the pancreatic beta cells to produce and secrete additional insulin is impaired.
However, Shiro Maeda of the RIKEN Center for Genomic Medicine in Yokohama points out that the relative importance of these mechanisms appears to differ between Eastern and Western populations. “Accumulating clinical evidence suggests that disability of insulin secretion contributes more to the pathogenesis of Japanese type 2 diabetes,” he says, “whereas insulin resistance seems more important for European type 2 diabetes.”
Getting the big picture
Very little is known about the genetic-level differences in pathology between the Japanese and Europeans. From several previous genome-wide association studies (GWAS), geneticists have identified several small sequence changes, also known as single-nucleotide polymorphisms (SNPs), which might be located near or within genes involved in type 2 diabetes. They have also identified several of these ‘susceptibility loci’. However, with the exception of a few small-scale Japanese studies, nearly all of these data were obtained exclusively from individuals of European ancestry.
In an effort to collect more information about Japanese-specific risk factors, Maeda and Takashi Kadowaki of The University of Tokyo recently headed up a large GWAS that matches the scale of its European counterparts both in terms of the numbers of subjects involved and in the number of genomic markers examined1. According to Maeda, their study of some 5,000 type 2 diabetes subjects and 3,000 controls for 459,359 SNPs, is one of the largest sample sizes for a single GWAS worldwide.
Maeda, Kadowaki and colleagues subjected 98 candidate SNPs with the strongest association to type 2 diabetes to an additional round of analysis in a second, independent, set of disease and control cohorts. Based on these data, they identified statistically significant disease linkage for SNPs at a number of different genomic loci (Fig. 2). One of these SNPs, KCNQ1, was identified in both of the previous Japanese GWAS as a risk factor in both Asians and Europeans, and this gene appears to participate in the regulation of glucose-induced insulin secretion.
The researchers’ study also flagged SNPs at two additional loci for which no association to type 2 diabetes had been previously reported. Both of these loci were subsequently validated in yet a third round of genomic screening, reinforcing the likelihood of their connection to diabetes.
Enigmatic risk factors
One of the newly identified loci, UBE2E2, encodes an enzyme that targets proteins for destruction by marking them with individual molecules of the small protein ubiquitin. It is expressed in a variety of tissues, including the liver, pancreas, muscle and fat. Based on several recent studies, researchers have suggested that the ubiquitination pathway may contribute to the efficient synthesis and secretion of insulin. Maeda, Kadowaki and colleagues noted that study subjects with the diabetes risk-associated UBE2E2 allele appeared to exhibit impairments in insulin regulation.
Strikingly, although the SNPs at this locus were also determined to be associated with type 2 diabetes for three other East Asian populations, in addition to various Japanese study groups, this association was not statistically significant for two European groups, consisting of a total of 6,980 subjects and 8,615 controls. “Although this population-specific effect needs to be validated further, the present study is the first to show the existence of a disease-susceptibility locus [for diabetes] in a population-specific manner with genome-wide significant levels of association,” says Maeda.
Despite escaping detection in previous large-scale GWAS, the second newly identified locus, C2CD4A-C2CD4B, showed significant association with type 2 diabetes in both Asian and European cohorts. C2CD4A-C2CD4B produces a pair of factors that appear to contribute to the maintenance of cell structure, and although relatively little is known about their function, both factors are expressed in many of the same tissues as UBE2E2. This represents the first indication that they might contribute to the pathology of type 2 diabetes.
Kadowaki, Maeda and colleagues are now scanning these two loci more carefully in an effort to identify potential mechanisms by which sequence variants in these regions might contribute to onset of diabetes. Maeda indicates that they are particularly keen to understand the biological basis for the apparent ethnicity-specific disease association of SNPs in the UBE2E2 locus.
At the same time, the identification of a novel locus that appears to contribute to risk of diabetes across population lines suggests that there may be a number of other susceptibility genes waiting to be discovered. “The identification of C2CD4A-C2CD4B as a common locus is really surprising, because this important locus has been missed in European GWAS,” says Maeda, “[and] we are now participating in international collaborations, both East Asian and trans-ethnic, to identify additional type 2 diabetes susceptibility loci.”
Shiro MaedaShiro Maeda was born in 1960 and is currently Laboratory Head at the Laboratory for Endocrinology and Metabolism, RIKEN Center for Genomic Medicine, where his research area is genetics for diabetic nephropathy and type 2 diabetes. He received his MD and PhD from Shiga University of Medical Science. He worked as a physician at Koka Public Hospital and Shiga University of Medical Science for next three years. From 1993 to 1996 he was a research fellow at the Department of Pathology, University of Michigan, where he researched osmotic response elements within the ALR2 gene. For the next two years, he did a residency at Shiga University of Medical Science in internal medicine, and emergency and critical medicine. In 1999, he was an instructor for the Third Department of Medicine, Shiga University of Medical Science, and then joined RIKEN the following year as a research scientist in the Laboratory for Genotyping, SNP Research Center. He was a Laboratory head at Laboratory for Diabetic Nephropathy between 2001 and 2008, and has been in his current post since 2008.
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences